Similar articles

• Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.

  Gabrilove JL, Sarokhan B, Cremieux P. Gabrilove JL, et al. J Clin Oncol. 2002 Jun 1;20(11):2757-8. doi: 10.1200/JCO.2002.20.11.2757. J Clin Oncol. 2002. PMID: 12039942 No abstract available.
• Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

  Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Gabrilove JL, et al. J Clin Oncol. 2001 Jun 1;19(11):2875-82. doi: 10.1200/JCO.2001.19.11.2875. J Clin Oncol. 2001. PMID: 11387360 Clinical Trial.
• Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.

  Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L. Patton J, et al. Oncologist. 2004;9(1):90-6. Oncologist. 2004. PMID: 14755018
• Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins.

  Pujade-Lauraine E, Topham C. Pujade-Lauraine E, et al. Oncology. 2005;68(2-3):122-9. doi: 10.1159/000086957. Epub 2005 Jul 7. Oncology. 2005. PMID: 16015034 Review.
• Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.

  Itri LM. Itri LM. Nephrol Dial Transplant. 2001 Dec;16(12):2289-93. doi: 10.1093/ndt/16.12.2289. Nephrol Dial Transplant. 2001. PMID: 11733616 Review. No abstract available.